Evaluation of a commercially developed indirect immunofluorescence system for the detection of antihuman immunodeficiency virus antibodies.
A commercially developed IFA system (Electro Nucleonics, Inc.) was compared to EIA (Abbott Laboratories) and WB (Bio-Rad, Inc.) for detection of HIV-1 antibodies. Of 91 EIA negative sera tested, 76 (83.5%) were negative, and 15 (16.5%) were equivocal by IFA on initial testing. Of 156 EIA positive sera tested, 18 were equivocal by either IFA or WB and could not be directly compared. Of 138 EIA positive sera directly comparable, IFA and WB agreed 137 times (99.3% correlation). Based on these findings, the commercially developed IFA system appears to be most useful as a supplementary test, similar to WB, rather than as a screening test.